Simeprevir (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Simeprevir" in English language version.

refsWebsite

Global rank English rank

13web.archive.org

1^st place

12nih.gov

4^th place

8doi.org

2^nd place

4fda.gov

447^th place

338^th place

3handle.net

102^nd place

76^th place

2hcvguidelines.org

low place

2semanticscholar.org

11^th place

8^th place

1tga.gov.au

3,984^th place

2,622^nd place

1drugs.com

399^th place

333^rd place

1books.google.com

3^rd place

1worldcat.org

5^th place

1olysio.com

low place

1merck.com

6,464^th place

5,671^st place

1medscape.com

719^th place

636^th place

1europa.eu

68^th place

117^th place

1bloomberg.com

99^th place

77^th place

1wsj.com

79^th place

65^th place

1hivandhepatitis.com

low place

1archive.today

14^th place

1medivir.se

low place

archive.today

Medivir announces TMC435 in an expanded clinical collaboration. Medivir. 18 April 2012.

bloomberg.com

West, Stephen. "Gilead Warns After Hepatitis Patient on Heart Drug Dies" Archived 2017-03-22 at the Wayback Machine. Published 21 March 2015.

books.google.com

Grubbs RH, O'Leary DJ (2015). Handbook of Metathesis, Volume 2: Applications in Organic Synthesis. John Wiley & Sons. p. 699. ISBN 9783527694020.

doi.org

Majumdar A, Kitson MT, Roberts SK (June 2016). "Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis". Alimentary Pharmacology & Therapeutics. 43 (12): 1276–92. doi:10.1111/apt.13633. PMID 27087015.
Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G (April 2015). "Which therapeutic option for hepatitis C virus genotype 1?". Scandinavian Journal of Gastroenterology. 50 (4): 470–8. doi:10.3109/00365521.2014.978364. PMID 25396710. S2CID 34382861.
Dugum M, O'Shea R (March 2014). "Hepatitis C virus: here comes all-oral treatment". Cleveland Clinic Journal of Medicine. 81 (3): 159–72. doi:10.3949/ccjm.81a.13155. PMID 24591471. S2CID 37838853.
Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. (April 2009). "In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor". Antimicrobial Agents and Chemotherapy. 53 (4): 1377–85. doi:10.1128/AAC.01058-08. PMC 2663092. PMID 19171797.
European Association for the Study of the Liver (August 2011). "EASL Clinical Practice Guidelines: management of hepatitis C virus infection". Journal of Hepatology. 55 (2): 245–64. doi:10.1016/j.jhep.2011.02.023. hdl:10447/88292. PMID 21371579.
Zein NN (April 2000). "Clinical significance of hepatitis C virus genotypes". Clinical Microbiology Reviews. 13 (2): 223–35. doi:10.1128/CMR.13.2.223-235.2000. PMC 100152. PMID 10755999.
Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, et al. (August 2014). "Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides". Antimicrobial Agents and Chemotherapy. 58 (8): 4555–64. doi:10.1128/AAC.02724-14. PMC 4135986. PMID 24867984.
Alamri MA, Tahir Ul Qamar M, Mirza MU, Bhadane R, Alqahtani SM, Muneer I, et al. (June 2020). "Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL^pro". Journal of Biomolecular Structure & Dynamics. 39 (13): 4936–4948. doi:10.1080/07391102.2020.1782768. PMC 7332866. PMID 32579061.

drugs.com

"Simeprevir". The American Society of Health-System Pharmacists. Archived from the original on 1 December 2016. Retrieved 30 November 2016.

europa.eu

ema.europa.eu

"Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free)". European Medicines Agency (EMA). 17 September 2018. Retrieved 4 February 2020.

fda.gov

"FDA ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING" (PDF). Food and Drug Administration. October 2013. Archived (PDF) from the original on 26 December 2014. Retrieved 24 October 2014.
"Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Archived from the original on 6 October 2016. Retrieved 6 October 2016.
"FDA approves new treatment for hepatitis C virus". Food and Drug Administration. 22 November 2013. Archived from the original on 16 December 2013.

accessdata.fda.gov

"Highlights of Prescribing Information Copegus" (PDF). August 2011. Archived (PDF) from the original on 3 November 2014. Retrieved 24 October 2014.

handle.net

hdl.handle.net

World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
European Association for the Study of the Liver (August 2011). "EASL Clinical Practice Guidelines: management of hepatitis C virus infection". Journal of Hepatology. 55 (2): 245–64. doi:10.1016/j.jhep.2011.02.023. hdl:10447/88292. PMID 21371579.

hcvguidelines.org

"Initial treatment of HCV infection". www.hcvguidelines.org. October 2016. Archived from the original on 7 December 2016. Retrieved 1 December 2016.
"Recommendations for Testing, Managing, and Treating Hepatitis C". 2014. Archived from the original on 16 October 2014. Retrieved 24 October 2014.

hivandhepatitis.com

"Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks". hivandhepatitis.com. 27 December 2012. Archived from the original on 13 March 2013.

medivir.se

Results from a phase IIa study evaluating Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients have been presented at CROI. 6 March 2013. Archived 16 October 2012 at the Wayback Machine

medscape.com

reference.medscape.com

"Olysio (simeprevir) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Archived from the original on 10 November 2016. Retrieved 10 November 2016.

merck.com

"Highlights of Prescribing Information PEGINTRON" (PDF). July 2014. Archived (PDF) from the original on 3 November 2014. Retrieved 24 October 2014.

nih.gov

pubmed.ncbi.nlm.nih.gov

Majumdar A, Kitson MT, Roberts SK (June 2016). "Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis". Alimentary Pharmacology & Therapeutics. 43 (12): 1276–92. doi:10.1111/apt.13633. PMID 27087015.
Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G (April 2015). "Which therapeutic option for hepatitis C virus genotype 1?". Scandinavian Journal of Gastroenterology. 50 (4): 470–8. doi:10.3109/00365521.2014.978364. PMID 25396710. S2CID 34382861.
Dugum M, O'Shea R (March 2014). "Hepatitis C virus: here comes all-oral treatment". Cleveland Clinic Journal of Medicine. 81 (3): 159–72. doi:10.3949/ccjm.81a.13155. PMID 24591471. S2CID 37838853.
Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. (April 2009). "In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor". Antimicrobial Agents and Chemotherapy. 53 (4): 1377–85. doi:10.1128/AAC.01058-08. PMC 2663092. PMID 19171797.
European Association for the Study of the Liver (August 2011). "EASL Clinical Practice Guidelines: management of hepatitis C virus infection". Journal of Hepatology. 55 (2): 245–64. doi:10.1016/j.jhep.2011.02.023. hdl:10447/88292. PMID 21371579.
Zein NN (April 2000). "Clinical significance of hepatitis C virus genotypes". Clinical Microbiology Reviews. 13 (2): 223–35. doi:10.1128/CMR.13.2.223-235.2000. PMC 100152. PMID 10755999.
Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, et al. (August 2014). "Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides". Antimicrobial Agents and Chemotherapy. 58 (8): 4555–64. doi:10.1128/AAC.02724-14. PMC 4135986. PMID 24867984.
Alamri MA, Tahir Ul Qamar M, Mirza MU, Bhadane R, Alqahtani SM, Muneer I, et al. (June 2020). "Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL^pro". Journal of Biomolecular Structure & Dynamics. 39 (13): 4936–4948. doi:10.1080/07391102.2020.1782768. PMC 7332866. PMID 32579061.

ncbi.nlm.nih.gov

Lin TI, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A, et al. (April 2009). "In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor". Antimicrobial Agents and Chemotherapy. 53 (4): 1377–85. doi:10.1128/AAC.01058-08. PMC 2663092. PMID 19171797.
Zein NN (April 2000). "Clinical significance of hepatitis C virus genotypes". Clinical Microbiology Reviews. 13 (2): 223–35. doi:10.1128/CMR.13.2.223-235.2000. PMC 100152. PMID 10755999.
Furihata T, Matsumoto S, Fu Z, Tsubota A, Sun Y, Matsumoto S, et al. (August 2014). "Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides". Antimicrobial Agents and Chemotherapy. 58 (8): 4555–64. doi:10.1128/AAC.02724-14. PMC 4135986. PMID 24867984.
Alamri MA, Tahir Ul Qamar M, Mirza MU, Bhadane R, Alqahtani SM, Muneer I, et al. (June 2020). "Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL^pro". Journal of Biomolecular Structure & Dynamics. 39 (13): 4936–4948. doi:10.1080/07391102.2020.1782768. PMC 7332866. PMID 32579061.

olysio.com

"OLYSIO (simeprevir) capsules, for oral use FULL PRESCRIBING INFORMATION". September 2014. Retrieved 24 October 2014.^{[permanent dead link]}

semanticscholar.org

api.semanticscholar.org

Brochot E, Helle F, François C, Castelain S, Capron D, Nguyen-Khac E, Duverlie G (April 2015). "Which therapeutic option for hepatitis C virus genotype 1?". Scandinavian Journal of Gastroenterology. 50 (4): 470–8. doi:10.3109/00365521.2014.978364. PMID 25396710. S2CID 34382861.
Dugum M, O'Shea R (March 2014). "Hepatitis C virus: here comes all-oral treatment". Cleveland Clinic Journal of Medicine. 81 (3): 159–72. doi:10.3949/ccjm.81a.13155. PMID 24591471. S2CID 37838853.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

"Simeprevir". The American Society of Health-System Pharmacists. Archived from the original on 1 December 2016. Retrieved 30 November 2016.
"Initial treatment of HCV infection". www.hcvguidelines.org. October 2016. Archived from the original on 7 December 2016. Retrieved 1 December 2016.
"Recommendations for Testing, Managing, and Treating Hepatitis C". 2014. Archived from the original on 16 October 2014. Retrieved 24 October 2014.
"Highlights of Prescribing Information Copegus" (PDF). August 2011. Archived (PDF) from the original on 3 November 2014. Retrieved 24 October 2014.
"Highlights of Prescribing Information PEGINTRON" (PDF). July 2014. Archived (PDF) from the original on 3 November 2014. Retrieved 24 October 2014.
"FDA ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING" (PDF). Food and Drug Administration. October 2013. Archived (PDF) from the original on 26 December 2014. Retrieved 24 October 2014.
"Olysio (simeprevir) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Archived from the original on 10 November 2016. Retrieved 10 November 2016.
"Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Archived from the original on 6 October 2016. Retrieved 6 October 2016.
West, Stephen. "Gilead Warns After Hepatitis Patient on Heart Drug Dies" Archived 2017-03-22 at the Wayback Machine. Published 21 March 2015.
"FDA approves new treatment for hepatitis C virus". Food and Drug Administration. 22 November 2013. Archived from the original on 16 December 2013.
"Medivir: Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection". The Wall Street Journal. 27 September 2013. Archived from the original on 24 November 2013.
"Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks". hivandhepatitis.com. 27 December 2012. Archived from the original on 13 March 2013.
Results from a phase IIa study evaluating Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients have been presented at CROI. 6 March 2013. Archived 16 October 2012 at the Wayback Machine

worldcat.org

search.worldcat.org

World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.

wsj.com

online.wsj.com

"Medivir: Simeprevir has been approved in Japan for the treatment of genotype 1 chronic hepatitis C infection". The Wall Street Journal. 27 September 2013. Archived from the original on 24 November 2013.